---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-108996"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2022-10-17T23:59:59+00:00"
generated_at: "2026-06-23T03:15:45.404536+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma announces positive Phase 3 RAPID trial results for etripamil in PSVT

## Summary
- Primary endpoint met: 64.3% of etripamil patients converted to sinus rhythm within 30 min vs 31.2% placebo (HR=2.62, p<0.001).
- Safety profile consistent with prior trials; no serious AEs related to etripamil; majority of AEs mild (68%) to moderate (31%).
- Pooled data show statistically significant reduction in medical interventions and ED visits.
- Company plans to submit NDA to FDA in mid-2023.

## SEC filing metadata
- accession: 0001104659-22-108996
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2022-10-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465922108996/0001104659-22-108996-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465922108996/tm2228338d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-108996
- JSON: https://secwatch.observer/filing/0001104659-22-108996.json
- Plain text: https://secwatch.observer/filing/0001104659-22-108996.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.